HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

ABSTRACT: Policy discussions about the feasibility of massively scaling up antiretroviral therapy (ART) to reduce HIV transmission and incidence hinge on accurately projecting the cost of such scale-up in comparison to the benefits from reduced HIV incidence and mortality. We review the available literature on modelled estimates of the cost of providing ART to different populations around the world, and suggest alternative methods of characterising cost when modelling several decades into the future. In past economic analyses of ART provision, costs were often assumed to vary by disease stage and treatment regimen, but for treatment as prevention, in particular, most analyses assume a uniform cost per patient. This approach disregards variables that can affect unit cost, such as differences in facto

SUBMITTER: Meyer-Rath G 

PROVIDER: S-EPMC3393674 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature